首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   397篇
  免费   27篇
  国内免费   34篇
儿科学   16篇
妇产科学   6篇
基础医学   87篇
口腔科学   10篇
临床医学   62篇
内科学   106篇
皮肤病学   3篇
神经病学   37篇
特种医学   3篇
外科学   31篇
综合类   18篇
预防医学   26篇
眼科学   10篇
药学   22篇
中国医学   2篇
肿瘤学   19篇
  2023年   4篇
  2022年   7篇
  2021年   10篇
  2020年   10篇
  2019年   7篇
  2018年   12篇
  2017年   8篇
  2016年   15篇
  2015年   14篇
  2014年   14篇
  2013年   16篇
  2012年   30篇
  2011年   37篇
  2010年   9篇
  2009年   18篇
  2008年   22篇
  2007年   46篇
  2006年   27篇
  2005年   11篇
  2004年   10篇
  2003年   15篇
  2002年   14篇
  2001年   12篇
  2000年   5篇
  1999年   12篇
  1998年   4篇
  1997年   5篇
  1996年   4篇
  1995年   5篇
  1994年   2篇
  1993年   5篇
  1992年   10篇
  1991年   5篇
  1989年   7篇
  1988年   8篇
  1987年   3篇
  1986年   2篇
  1985年   3篇
  1984年   1篇
  1983年   1篇
  1982年   1篇
  1980年   1篇
  1978年   1篇
  1977年   2篇
  1969年   1篇
  1966年   1篇
  1957年   1篇
排序方式: 共有458条查询结果,搜索用时 15 毫秒
31.
32.
We assessed the efficacy and safety of oral single doses of 0.5 and 1 g metamizol vs. 1 g acetylsalicylic acid (ASA) in 417 patients with moderate episodic tension-type headache included in a randomized, double-blind, placebo- and active-controlled, parallel, multicentre trial. Eligibility criteria included 18-65 years of age, history of at least two episodes of tension-type headache per month in the 3 months prior to enrollment, and successful previous pain relief with a non-opioid analgesic. Treatment arms were metamizol 0.5 g (n = 102), metamizol 1 g (n = 108), ASA 1 g (n = 102) and placebo (n = 105). The analgesic efficacy of 0.5 and 1 g metamizol vs. placebo was highly statistically significant (alpha: 0.025; one-sided) for sum of pain intensity differences, maximum pain intensity difference, number of patients with at least 50% pain reduction, time to 50% pain reduction, maximum pain relief and total pain relief. A trend towards an earlier onset of a more profound pain relief of 0.5 and 1 g metamizol over 1 g ASA was noticed. All medications including placebo were almost equally safe and well tolerated.  相似文献   
33.
Taenia solium cysticercosis seriously affects human health when localised in the central nervous system (CNS) and causes great economic loss in pig husbandry in rural areas of endemic countries. Increasing the resistance to the parasite in the obligatory host pig may help in curbing transmission. Three synthetic peptides based on protein sequences of the murine parasite Taenia crassiceps, which had previously been shown to induce protection in mice against homologous challenge, were tested as a vaccine against T. solium cysticercosis in pigs. Vaccinated and unvaccinated piglets (240 in all) were distributed in pairs among the peasants' households of two rural villages in Mexico in which 14% of the native pigs were cysticercotic. Ten to twelve months later, the effect of vaccination was evaluated at necropsy. Vaccination decreased the total number of T. solium cysticerci (98.7%) and reduced the prevalence (52.6%). The natural challenge conditions used in this field trial strengthen the likelihood of successful transmission control to both pig and human through a large-scale pig vaccination program. We believe this is a major contribution in anticysticercosis vaccine development as these rather simple yet protective peptides are potentially more cost-effective to produce and less variable in results than antigens that are more complex.  相似文献   
34.
OBJECTIVE: To search for somatic activating mutations of gonadotropin receptor (FSH-R and LH/chorionic gonadotropin receptor [CG-R]) genes as a cause of sex cord stromal tumors. DESIGN: Molecular studies in human tissue. SETTING: University hospital. SPECIMEN(S): Eight granulosa cell tumors collected from paraffin-embedded tissue, eight Leydig cell tumors, and three thecomas collected from fresh-frozen or paraffin-embedded tissue. INTERVENTION(S): Tumor samples were used for DNA extraction. The entire exon 11 of the LH/CG-R gene and a hot spot for gonadotropin receptor activating mutations on exon 10 of the FSH-R gene were amplified by polymerase chain reaction. The former was analyzed by denaturing gradient gel electrophoresis and automatic direct sequencing, and the latter by automatic direct sequencing. MAIN OUTCOME MEASURE(S): Results of denaturing gradient gel electrophoresis and automatic direct sequencing. RESULT(S): No somatic activating mutation was detected in exon 11 of the LH/CG-R gene in eight Leydig cell tumors and three thecomas. In addition, no mutations were detected in eight granulosa cell tumors in the hot spot for activating mutations in exon 10 of the FSH-R gene. CONCLUSION(S): Somatic activating mutations of gonadotropin receptors seem to play no relevant role in the development of sex cord stromal tumors.  相似文献   
35.
小鼠脑缺血后的能量代谢改变和药物的作用   总被引:35,自引:0,他引:35  
应用部分结扎小鼠颈总动脉(包括迷走神经)及小鼠断头法引起脑缺血后,脑组织的ATP和磷酸肌酸明显降低,乳酸明显升高。部分结扎颈动脉出现四肢无力、转圈及昏睡等症状,其严重程度与脑能量代谢改变相平行。皮下注射尼莫地平、硝苯吡啶、尼卡地平和三七皂甙对脑缺血有一定保护作用。苯巴比妥钠能改善正常和脑缺血小鼠的脑能量代谢,人参皂甙Rb1可降低正常小鼠脑乳酸含量。  相似文献   
36.
目的 探讨在外科术后专科康复护理中深化护理文化建设的实践与效果。方法 选择符合诊断标准的乳腺癌改良根治术、脑卒中偏瘫及脊髓损伤、腰椎间盘突出患者随机分成实验组和对照组,实验组患者术后应用自制辅助卧位枕辅助维持康复体位及VCD光盘辅助指导功能锻炼,对照组采用传统方法辅助卧位及健康教育方法。结果 实验组患者疼痛减轻,舒适度及依从性优于对照组(P〈0.05);特定知识的知晓率及功能锻炼正确率高于对照组(P〈0.05)。结论 自制系列辅助康复卧位枕及VCD光盘辅助指导功能锻炼的应用可让患者感到舒适、方便,实践了人性化护理与专科护理技术的有机结合,丰富了护理文化的内涵,值得推广。  相似文献   
37.
38.
目的:为改善生物材料聚羟基丁酸己酸酯(PHBHHx)的力学性能和聚碳酸亚丙酯(PPC)的可加工性,将两者共混,制备不同比例的共混材料,并对共混膜上血管平滑肌细胞的黏附和共混材料制成的管形支架的力学性能进行评价,以选出合适比例的共混材料作为血管组织工程支架。 方法:实验于2006-08/2007-04在清华大学生物科学与技术系生物膜与膜生物工程国家重点实验室完成。①制备5种不同比例(PHBHHx∶PPC分别为0∶10,3∶7,5∶5,7∶3,10∶0)的共混材料,利用CCK-8试剂测定兔主动脉平滑肌细胞在共混膜上培养24h后的黏附数量。②采用热致相分离和冷冻干燥法制备管形支架,通过反复浸渍和晾干,在多孔支架外层形成一层晾干的膜层。利用扫描电镜观察支架形貌、压汞仪测量孔隙率和孔径分布,利用自制装置以6.65kPa/s的加压速度测定管形支架的破裂强度,万能材料试验机测定支架的缝合强度,以羊颈动脉为对照。 结果:①兔主动脉平滑肌细胞在各种膜上培养24h后,在5∶5比例PHBHHXx/PPC共混膜和PPC膜上相对黏附量高于PHBHHXx膜(P〈0.05)。②PHBHHx和共混材料均可制备成管形支架,而单纯PPC支架在制备晾干层时溶化,无法维持原形。管形支架的孔径随PPC含量的增加而增大,孔隙率提高。③支架的破裂强度与羊颈动脉相似(P〉0.05);缝合强度均强于羊颈动脉,以5∶5和3∶7PHBHHx/PPC共混材料制备的管形支架的缝合强度高于PHBHHx支架。 结论:①与PHBHHx相比,5∶5PHBHHx/PPC共混膜和PPC膜上兔主动脉平滑肌细胞的黏附更好。②共混材料均可以制备成管形支架,并且力学强度符合移植的要求,缝合强度以5∶5和3∶7的PHBHHx/PPC共混材料最佳。  相似文献   
39.
40.

Background/Purpose

Exclusion criteria for enema reduction of intussusception are still a matter of debate. The current study aimed to search for risk factors and to design and evaluate a predictive model of air enema failure.

Methods

The design was a cross-sectional study. The study was conducted at a tertiary university hospital. The participants were 164 children (mean [SD] age of 11.6 [10.7] months) with intestinal intussusception. The intervention done was pneumatic reduction only contraindicated in case of peritonitis and/or sepsis. For main outcome measures, logistic regression analysis was used to estimate the contribution of clinical parameters (age, sex, weight, clinical evolution, temperature, rectal bleeding, white blood cell count, and neutrophils) to predict the risk of enema failure. To evaluate the discriminating power of the model, a receiver operating characteristic curve was constructed, and the effectiveness at different cutoffs was calculated.

Results

Overall efficacy was 85%; manual reduction was performed in 12 (7.3%) cases, and there were 9 (6.5%) recurrences. Multivariable analysis adjusted for age and sex revealed that delayed diagnosis (evolution >24 hours) and raised neutrophils (%) were associated with failure: odds ratio of 11.52 (95% CI, 3.73-35.54) and 1.06 (95% CI, 1.02-1.11), respectively. The area under the receiver operating characteristic curve was 0.826 (95% CI, 0.740-0.912). At the best cutoff (0.15), the positive predictive value was 35% and the negative 93%. At the cutoff of 0.50, the positive predictive value was 70% and the negative 87%; the sensitivity was 29%.

Conclusions

The efficacy and safety of pneumatic reduction in childhood intussusception was confirmed. Delayed diagnosis and neutrophils significantly predict outcome. Despite consistent high negative predictive values, the model has low effectiveness in predicting enema failure and may not be clinically relevant; there is no rationale for stricter exclusion criteria.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号